Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,085Revenue $M54.8Net Margin (%)-148.1Z-Score1.1
Enterprise Value $M1,000EPS $-0.7Operating Margin %-140.1F-Score2
P/E(ttm))0Cash Flow Per Share $-0.2Pre-tax Margin (%)-148.1Higher ROA y-yN
Price/Book27.010-y EBITDA Growth Rate %8.2Quick Ratio4.4Cash flow > EarningsY
Price/Sales18.15-y EBITDA Growth Rate %-0.6Current Ratio4.6Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-56.3Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)2ROE % (ttm)-307.2Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M125ROI % (ttm)-92.5Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
HALOJean-Marie Eveillard 2014-09-30 Add0.02%$8.67 - $10.2
($9.52)
$ 8.65-9%Add 30.25%3,640,480
HALOJohn Burbank 2014-09-30 Reduce$8.67 - $10.2
($9.52)
$ 8.65-9%Reduce -20.19%19,573
HALOJean-Marie Eveillard 2014-06-30 Add0.03%$7.09 - $12.31
($8.46)
$ 8.652%Add 94.94%2,795,080
HALOKen Fisher 2014-06-30 Buy 0.02%$7.09 - $12.31
($8.46)
$ 8.652%New holding, 791760 sh.791,760
HALOJohn Burbank 2014-06-30 Add$7.09 - $12.31
($8.46)
$ 8.652%Add 55.47%24,523
HALOJohn Burbank 2014-03-31 Buy 0.01%$12.11 - $17.57
($14.89)
$ 8.65-42%New holding, 15773 sh.15,773
HALOJean-Marie Eveillard 2013-12-31 Buy 0.05%$9.66 - $15.7
($12.86)
$ 8.65-33%New holding, 1294580 sh.1,294,580
HALOJohn Burbank 2012-12-31 Sold Out -0.17%$4.82 - $7.07
($5.83)
$ 8.6548%Sold Out0
HALOJohn Burbank 2012-09-30 Add0.07%$4.28 - $9.78
($7.29)
$ 8.6519%Add 66.67%500,000
HALOJohn Burbank 2012-06-30 Add0.03%$7.32 - $13
($8.75)
$ 8.65-1%Add 50%300,000
HALOJohn Burbank 2012-03-31 Buy 0.09%$9.22 - $13.35
($10.53)
$ 8.65-18%New holding, 200000 sh.200,000
HALOGeorge Soros 2011-12-31 Sold Out -0.0018%$5.72 - $9.73
($8.21)
$ 8.655%Sold Out0
HALOGeorge Soros 2011-09-30 Buy $5.62 - $7.29
($6.61)
$ 8.6531%New holding, 17100 sh.17,100
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

HALO is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
HALO Jean-Marie Eveillard 2014-09-303,640,4802.90.08+30.25%
HALO Ken Fisher 2014-09-30762,7800.610.02-3.66%
HALO John Burbank 2014-09-3019,5730.020-20.19%
Premium Most recent portfolio changes are included for Premium Members only!


HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.92-14.35view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.9-14.16view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.96-23.29view
Engler RobertDirector 2014-08-14Sell35,000$9.96-23.29view
Engler RobertDirector 2014-05-15Sell126,700$7.561.06view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.13-16.32view
Shepard H. MichaelVP, Chief Scientific Officer 2013-08-19Sell10,000$7.117.45view
FALBERG KATHRYN EDirector 2013-08-14Buy100,000$6.8212.02view
Engler RobertDirector 2012-11-29Buy15,000$5.5737.16view
Shaffer James PVP & Chief Commercial Officer 2012-11-14Buy20,000$5.2246.36view

Press Releases about HALO :

    Quarterly/Annual Reports about HALO:

      News about Halo:

      Articles On GuruFocus.com
      Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      comment on HALO May 12 2013 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) May 07 2010 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Nov 06 2009 
      Halozyme Therapeutics Reports Second Quarter 2009 Financial Results Aug 07 2009 
      Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 07 2009 
      Halozyme to Host Conference Call and Webcast on August 7 to Discuss Second Quarter 2009 Financial Re Jul 31 2009 

      More From Other Websites
      Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize... Dec 17 2014
      Halozyme Therapeutics Enters A Global Collaboration With Janssen To Develop And Commercialize... Dec 17 2014
      Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium... Dec 12 2014
      Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium... Dec 12 2014
      Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
      Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
      Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Nov 25 2014
      Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference Nov 25 2014
      HALOZYME THERAPEUTICS INC Financials Nov 19 2014
      10-Q for Halozyme Therapeutics, Inc. Nov 12 2014
      Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings Nov 11 2014
      Halozyme Therapeutics meets 3Q profit forecasts Nov 10 2014
      Halozyme Therapeutics meets 3Q profit forecasts Nov 10 2014
      Halozyme Therapeutics Plummets On Q3 Losses Nov 10 2014
      HALOZYME THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2014
      Halozyme Reports Third Quarter 2014 Financial Results Nov 10 2014
      Q3 2014 Halozyme Therapeutics Inc Earnings Release - After Market Close Nov 10 2014
      Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference Nov 05 2014
      Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference Nov 05 2014
      Halozyme to Host Third Quarter 2014 Financial Results Conference Call Nov 03 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK